SLShubham Lahan

Shubham Lahan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shubham Lahan has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lipoprotein(a) and Coronary Plaque in Asymptomatic Individuals: The Miami Heart Study at Baptist Health South Florida

    by Reed Mszar, Miguel Cainzos-Achirica, Javier Valero-Elizondo, Shubham Lahan, Sadeer G. Al-Kindi, Renato Quispe, Shozab S. Ali, Lara Arias, Anshul Saxena, Svati H. Shah, et al.

    BACKGROUND: Elevated levels of lipoprotein(a) (Lp(a)) are independently associated with an increased risk of atherosclerotic cardiovascular disease events. However, the mechanisms driving this association are poorly understood. We aimed to evaluate the association between Lp(a) and coronary plaque characteristics in a contemporary US cohort without clinical atherosclerotic cardiovascular disease, undergoing coronary computed tomography angiography, the noninvasive gold standard for the assessment of coronary atherosclerosis. METHODS: We used baseline data from the Miami Heart Study—a community-based, prospective cohort study—which included asymptomatic adults aged 40 to 65 years evaluated using coronary computed tomography angiography. Those taking any lipid-lowering therapies were excluded. Elevated Lp(a) was defined as ≥125 nmol/L. Outcomes included any plaque, coronary artery calcium score >0, maximal stenosis ≥50%, presence of any high-risk plaque feature (positive remodeling, spotty calcification, low-attenuation plaque, napkin ring), and the presence of ≥2 high-risk plaque features. RESULTS: Among 1795 participants (median age, 52 years; 54.3% women; 49.6% Hispanic), 291 (16.2%) had Lp(a) ≥125 nmol/L. In unadjusted analyses, individuals with Lp(a) ≥125 nmol/L had a higher prevalence of all outcomes compared with Lp(a) P <0.001). CONCLUSIONS: In this contemporary analysis, elevated Lp(a) was independently associated with the presence of coronary plaque. Larger studies are needed to confirm the strong association observed with the presence of multiple high-risk coronary plaque features.


  • Open Access

    Systemic Inflammation and CT-Derived Coronary Plaque Characteristics Among Asymptomatic US Adults: The Miami Heart Study

    by Shubham Lahan, Kobina Hagan, Miguel Cainzos-Achirica, Javier Valero-Elizondo, Shozab S. Ali, Lara Arias, Anshul Saxena, Theodore Feldman, Michael J. Blaha, Michael D. Shapiro, et al.

    Objective: We aimed to evaluate the association between inflammatory markers and coronary plaque features on coronary computed tomography angiography (CCTA) among asymptomatic individuals. Methods: Baseline data from Miami Heart Study — an ongoing prospective community-based study of a primary prevention cohort from the Greater Miami Area without prior known CAD — were used for this cross-sectional analysis. Independent variables included high-sensitivity C-reactive protein (hsCRP; 0, CAC>100, maximal stenosis >50%, and high-risk plaque. Multivariable logistic regression models were constructed to evaluate the association between inflammatory markers and coronary plaque features. Results: We evaluated 2,342 participants (50.4% men; mean age 53.4±6.7 years, 47% Hispanic, 43% non-Hispanic White, 8.3% diabetes, 56% hypertension, 22% on statin therapy). After adjusting for age, sex, and race/ethnicity, hsCRP ≥2 mg/L was associated with increased odds of having any plaque on CCTA [odds ratio (OR), 1.31 (95% confidence interval [CI], 1.09–1.58)] and stenosis ≥ 50% [OR, 1.69 (95% CI, 1.18–2.41)]. participants with IL–6 levels in 3 rd tertile were associated with higher odds of detecting any plaque [OR, 1.59 (95% CI, (1.27–1.99)], CAC >0 [OR, 1.34 (95% CI, 1.06–1.69)], ≥50% stenosis [OR, 2.41 (95% CI, 1.56–3.81)], and any high-risk plaque [OR, 2.41 (95% CI, 1.56–3.81)] Further adjustment for LDL, diabetes, hypertension, obesity, and tobacco use yielded nonsignificant associations. Conclusion: Elevated levels of hsCRP and IL–6 are associated with the presence of coronary plaque and stenosis on CCTA when adjusted for demographics. However, these associations became nonsignificant after adjusting for additional cardiovascular risk factors. Our findings suggest a role of systemic inflammation as a mediator of the effect of cardiovascular risk factors on coronary plaque burden.

  • Coronary Atherosclerosis Across the Glycemic Spectrum Among Asymptomatic Adults: The Miami Heart Study at Baptist Health South Florida

    by Kershaw V. Patel, Matthew J. Budoff, Javier Valero-Elizondo, Shubham Lahan, Shozab S. Ali, Mohamad B. Taha, Michael J. Blaha, Ron Blankstein, Michael D. Shapiro, Ambarish Pandey, et al.

    BACKGROUND: The contemporary burden and characteristics of coronary atherosclerosis, assessed using coronary computed tomography angiography (CCTA), is unknown among asymptomatic adults with diabetes and prediabetes in the United States. The pooled cohort equations and coronary artery calcium (CAC) score stratify atherosclerotic cardiovascular disease risk, but their association with CCTA findings across glycemic categories is not well established. METHODS: Asymptomatic adults without atherosclerotic cardiovascular disease enrolled in the Miami Heart Study were included. Participants underwent CAC and CCTA testing and were classified into glycemic categories. Prevalence of coronary atherosclerosis (any plaque, noncalcified plaque, plaque with ≥1 high-risk feature, maximal stenosis ≥50%) assessed by CCTA was described across glycemic categories and further stratified by pooled cohort equations–estimated atherosclerotic cardiovascular disease risk and CAC score. Adjusted logistic regression was used to evaluate the associations between glycemic categories and coronary outcomes. RESULTS: Among 2352 participants (49.5% women), the prevalence of euglycemia, prediabetes, and diabetes was 63%, 30%, and 7%, respectively. Coronary plaque was more commonly present across worsening glycemic categories (euglycemia, 43%; prediabetes, 58%; diabetes, 69%), and similar pattern was observed for other coronary outcomes. In adjusted analyses, compared with euglycemia, prediabetes and diabetes were each associated with higher odds of any coronary plaque (OR, 1.30 [95% CI, 1.05–1.60] and 1.75 [1.17–2.61], respectively), noncalcified plaque (OR, 1.47 [1.19–1.81] and 1.99 [1.38–2.87], respectively), and plaque with ≥1 high-risk feature (OR, 1.65 [1.14–2.39] and 2.53 [1.48–4.33], respectively). Diabetes was associated with stenosis ≥50% (OR, 3.01 [1.79–5.08]; reference=euglycemia). Among participants with diabetes and estimated atherosclerotic cardiovascular disease risk <5%, 46% had coronary plaque and 10% had stenosis ≥50%. Among participants with diabetes and CAC=0, 30% had coronary plaque and 3% had stenosis ≥50%. CONCLUSIONS: Among asymptomatic adults, worse glycemic status is associated with higher prevalence and extent of coronary atherosclerosis, high-risk plaque, and stenosis. In diabetes, CAC was more closely associated with CCTA findings and informative in a larger population than the pooled cohort equations.


  • Sutureless Perceval Valve: Size Matters

    by Adham Elmously, Shubham Lahan, Qasim Al Abri, Moritz C. Wyler von Ballmoos, Mahesh Ramchandani


  • Open Access

    Atherosclerotic Cardiovascular Disease and Health-Related Quality of Life Among Adults in the United States: National Health Interview Survey 2013-2017

    by Kobina K. Hagan, Zulqarnain Javed, Isaac Acquah, Tamer Yahya, Javier Valero-Elizondo, Adnan A. Hyder, Elias Mossiolas, Shubham Lahan, Miguel Cainzos-Achirica, Khurram Nasir

    Background: A brief health-related quality of life (HRQoL) tool with construct validity for atherosclerotic cardiovascular disease (ASCVD) may facilitate integration into healthcare delivery. We examined ASCVD-related changes in the Health and Activity Limitation Index (HALex), a generic HRQoL measure comprising perceived health and activity limitation. Methods: Using data of 155,130 respondents of the National Health Interview Survey 2013-2017, we evaluated HALex scores by ASCVD (angina, heart attack, and stroke). Lower HALex scores reflected worse HRQoL and a 0.03 change was regarded as the threshold for clinical significance. Multivariable two-part models were used to assess HALex changes (β, 95%CI) associated with ASCVD overall and in sex, age, and race/ethnicity groups. Results: Overall, participants with ASCVD (6.8%, representing 15.7 million adults) had lower HALex scores (0.67) than those without ASCVD (0.87). Females, age ≥ 65 years, and non-Hispanic Blacks had the lowest HALex scores. Overall, ASCVD was associated with a substantial decrement in HALex (-0.10, [-0.10, -0.09]). Interactions between ASCVD and sex, and race/ethnicity were both significant (p < 0.001). ASCVD-associated decrement in HALex was clinically greater in: females (-0.11, [-0.12, -0.10]) than in males (-0.08, [-0.09, -0.07]); and non-Hispanic Black (-0.13, [-0.15, -0.1]) than in non-Hispanic White (-0.09, [-0.10, -0.08]). Though ASCVD impact on HALex was greater in age 18-64 years (-0.09, [-0.10, -0.08]), it was not statistically different from the elderly (-0.06, [-0.07, -0.06]). Conclusions: ASCVD was consistently associated with lower HRQoL, as measured by HALex, across major demographics. HALex presents a feasible HRQoL tool to implement in healthcare.

  • Open Access

    Network Meta-Analysis Comparing the Short- and Long-Term Outcomes of Alternative Access for Transcatheter Aortic Valve Replacement

    by Sagar Ranka, Shubham Lahan, Adnan K. Chhatriwalla, Keith B. Allen, Michael Chiang, Brian O'NEill, Sadhika Verma, Dee Dee Wang, James Lee, Tiberio Frisoli, et al.


  • MORTALITY TRENDS IN HEART FAILURE AND DIFFERENCES BY RACE AND SEX IN THE UNITED STATES: 1999 - 2019

    by Amandeep Goyal, Shubham Lahan, Poonam Bhyan, Sagar Ranka, Suveenkrishna Pothuru, Harsh Mehta, Tarun Dalia, Neelkumar Patel, Prakash Acharya, Tai Thien Tan Tri Truyen, et al.

  • In-Hospital Characteristics and 30-Day Readmissions for Acute Myocardial Infarction and Major Bleeding in Patients With Active Cancer

    by Shubham Lahan, Aditya Bharadwaj, Richard Cheng, Purvi Parwani, Robert Miller, Winson Cheung, Christopher Bianco, Babikir Kheiri, Mohammed Osman, Mohamed Mohamed, et al.


  • Open Access

    Network Meta-Analysis Comparing the Short and Long-Term Outcomes of Alternative Access for Transcatheter Aortic Valve Replacement

    by Sagar Ranka, Shubham Lahan, Adnan K. Chhatriwalla, Keith B. Allen, Sadhika Verma, Pedro Villablanca

    Objectives: This study aimed to compare short- and long-term outcomes following various alternative access routes for transcatheter aortic valve replacement (TAVR). Methods: Thirty-four studies with a pooled sample size of 30,986 records were selected by searching PubMed and Cochrane library databases from inception through 11 th June 2021 for patients undergoing TAVR via 1 of 6 different access sites: Transfemoral (TF), Transaortic (TAO), Transapical (TA), Transcarotid (TC), Transaxillary/Subclavian (TSA), and Transcaval (TCV). Data extracted from these studies were used to conduct a frequentist network meta-analysis with a random-effects model using TF access as a reference group. Results: Compared with TF, both TAO [RR 1.91, 95% CI (1.46–2.50)] and TA access [RR 2.12, 95%CI (1.84–2.46)] were associated with an increased risk of 30-day mortality. No significant difference was observed for stroke, myocardial infarction, major bleeding, conversion to open surgery, and major adverse cardiovascular or cerebrovascular events in the short-term (≤ 30 days). Major vascular complications were lower in TA [RR 0.43, (95% CI, 0.28-0.67)] and TC [RR 0.51, 95% CI (0.35-0.73)] access compared to TF. The 1-year mortality was higher in the TAO [RR of 1.35, (95% CI, 1.01–1.81)] and TA [RR 1.44, (95% CI, 1.14–1.81)] groups. Conclusion: Non-thoracic alternative access site utilization for TAVR implantation (TC, TSA and TCV) is associated with similar outcomes to conventional TF access. Thoracic TAVR access (TAO and TA) is associated with increased short and long-term mortality.